Document ID: chunk:federal_register_of_legislation:F2024C01228:reg:110
Version: federal_register_of_legislation:F2024C01228
Segment Type: reg
Provision Reference: reg 110
Character Range: 65471–67559

110   Vaccine                                                                                                                                                                                                                                                                                Prevenar 13        Injection (0.5mL)                                                                 Polysaccharides of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F ‑ 2.2 µg of each of serotype, and 4.4 μg of serotype 6B                                                                                                                                                                                                   2 or 3 doses of a primary course plus a booster dose
      Pneumococcal (conjugate, 13 valent)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 or a single supplementary dose
      Circumstances
      Vaccine may be provided:
       (a) to a child who is about 2, 4 or 12 months old, but less than 24 months old; or
       (b) in the circumstances set out in subsection 7(1); or
       (c) to a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal haemoglobinuria who have an inadequate clinical response or are intolerant to treatment with eculizumab or ravulizumab.